panalo999 Segall Bryant & Hamill LLC bought a new position in LivaNova PLC ( NASDAQ:LIVN – Free Report ) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 40,477 shares of the company’s stock, valued at approximately $2,127,000. Segall Bryant & Hamill LLC owned about 0.07% of LivaNova as of its most recent filing with the SEC. Other hedge funds and other institutional investors have also bought and sold shares of the company. Fifth Third Bancorp raised its holdings in shares of LivaNova by 97.1% during the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after purchasing an additional 332 shares during the last quarter. Hexagon Capital Partners LLC raised its stake in LivaNova by 117.8% during the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after buying an additional 370 shares during the last quarter. Lazard Asset Management LLC bought a new position in shares of LivaNova during the 1st quarter valued at $84,000. Canada Pension Plan Investment Board purchased a new position in shares of LivaNova in the 2nd quarter worth $88,000. Finally, Acadian Asset Management LLC bought a new stake in shares of LivaNova in the first quarter worth $94,000. Institutional investors own 97.64% of the company’s stock. Wall Street Analyst Weigh In A number of research analysts have weighed in on LIVN shares. The Goldman Sachs Group started coverage on LivaNova in a report on Friday, October 4th. They issued a “buy” rating and a $65.00 target price on the stock. StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 16th. Robert W. Baird boosted their target price on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Mizuho decreased their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. Finally, Needham & Company LLC reissued a “buy” rating and set a $75.00 price objective on shares of LivaNova in a research report on Tuesday, November 12th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $69.17. LivaNova Stock Performance Shares of NASDAQ LIVN opened at $51.32 on Friday. The stock has a market cap of $2.79 billion, a PE ratio of 122.19 and a beta of 1.01. LivaNova PLC has a 1 year low of $42.75 and a 1 year high of $64.47. The firm has a fifty day moving average price of $52.13 and a 200-day moving average price of $52.52. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. LivaNova Profile ( Free Report ) LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. Further Reading Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC ( NASDAQ:LIVN – Free Report ). Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter .The NFL has faced ongoing controversy for years regarding the potential link between chronic traumatic encephalopathy (CTE) and football-related injuries, with no resolution in sight. More News: Blood Test Can Benefit NFL Concussion Return-to-Play Decisions Although the league settled a lawsuit filed by over 4,500 former players who claimed the NFL downplayed the risks of brain trauma, the family of Ed Lothamer, a former defensive tackle who played eight seasons for the Kansas City Chiefs, argues that the league treats players with CTE as "throwaways" and is "just waiting for everyone to die." In a sobering new profile with The Kansas City Star , Ryan Lothamer-Welch, daughter of the deceased Chiefs player, went into detail regarding feeling "shunned" by the NFL due to her father's struggle with CTE. Despite the settled lawsuit, Lothamer-Welch feels that the NFL is doing little for players diagnosed with CTE. "I felt like they treated a lot of the guys that built that league on their backs like they were throwaways ..." Lothamer-Welch said. "It's just human nature. I mean, people care about what's happening today. They're not so interested in what happened yesterday or what's going to happen 10 years down the road." It is worth noting for context that the $765 million settlement by the NFL , which was intended to help cover treatment for players with CTE, dementia, or other brain-related illnesses after suffering on-field concussions, has been heavily criticized and accused of "routinely [failing] to deliver money and medical care to former players suffering from dementia and CTE." According to an investigation by The Washington Post , the NFL has allegedly failed to follow through on its responsibility to provide payouts, exploiting medical loopholes to avoid covering these expenses. After reviewing 15,000 pages of documents from more than 100 former players, the Post said players regularly saw "their claims denied by the administrative law firm that oversees the settlement. Reportedly, medical personnel who worked for the NFL "simply overruled physicians who actually evaluated players" and would reclassify dementia symptoms on non-football-related causes. Over a dozen players "failed to qualify for settlement money or medical care and then died, only to have CTE confirmed via autopsy." A recent survey by JAMA Neurology found that one-third of former professional football players suspect they suffer from CTE); the study is one of the most extensive to explore former NFL players' perceptions of their cognitive health. Ed Lothamer passed away in 2022, at the age of 80. Following his death, his family donated his brain to the UNITE Brain Bank, where researchers confirmed a diagnosis of stage 4 CTE, the most severe form of the condition. He had been drafted by the Chiefs in 1964 and was part of a defense renowned for its future Pro Football Hall of Famers. Despite numerous injuries, he played in 88 games and started 35 as the Chiefs appeared in two of the first four Super Bowls. "We were told he had some type of "dementia," with some forward-thinking doctors alluding to possible CTE and he had gotten a number of opinions over the years about his volatile and diminishing condition..." Lothamer-Welch wrote in a personal story at the Concussion Legacy Foundation . "My father made $42,000 during his final season in the NFL , which we now realize was the price he exchanged for his brain." More News: Professional Athletes' Homes Are Being Targeted by Robbery Ring Although Lothamer was a plaintiff in the settlement and had been formally diagnosed with Alzheimer's in 2016, his case is among many that the NFL has managed to sidestep, offering neither a payout nor any acknowledgment. To the Lothamer family, this appears to be part of a deliberate strategy by the league, even as they continue to hope that an attorney might help them secure compensation and, perhaps, some form of validation from the NFL . Instead, they've felt increasingly discouraged by the legal process. "They are just waiting for everybody to die," Elisabeth Lothamer, the widow of the former Chiefs player said. "I mean, it's just what they're doing." For more on the NFL , head to Newsweek Sports .

Global Payments Inc. (NYSE:GPN) Shares Sold by Empowered Funds LLCNone

Swiss National Bank Sells 2,100 Shares of Olin Co. (NYSE:OLN)

NoneNone